Use of AAC-11 inhibitors for the treatment of viral infection
The present invention relates to methods and pharmaceutical compositions for the treatment of viral infection.
1. A method for treating a viral an HIV infection in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of an AAC-11 inhibitor compound to treat said viral HIV infection,
wherein said AAC-11 inhibitor compound is a polypeptide comprising or consisting of
i) an amino acid sequence ranging from the phenylalanine residue at position 379 to the leucine residue at position 391 in SEQ ID NO:1 or,
ii) an amino acid sequence having at least 70% identity with the amino acid sequence ranging from the phenylalanine residue at position 379 to the leucine residue at position 391 in SEQ ID NO:1, or
iiiii) an amino acid sequence which is a retro-inverso of the amino acid sequence ranging from the phenylalanine residue at position 379 to the leucine residue at position 391 in SEQ ID NO:1 or,
iv) an amino acid sequence which is retro-inverso of the amino acid sequence having at least 70% identity with the amino acid sequence ranging from the phenylalanine residue at position 379 to the leucine residue at position 391 in SEQ ID NO:1.
2. The method according to claim 1 wherein said AAC-11 inhibitor compound is a fusion protein comprising the polypeptide fused to at least one heterologous polypeptide.
3. The method according to claim 2 wherein the at least one heterologous polypeptide is a cell-penetrating peptide.